AGENDA

Uniform Formulary Beneficiary Advisory Panel (BAP)
For the August 2022 DoD Pharmacy and Therapeutics Committee Meetings
September 29, 2022 at 10:00 AM Eastern Daylight Saving Time

Virtual Meeting

- **Administrative Meeting: 9:00 AM – 9:45 AM Eastern Daylight Saving Time (General session starts at 10:00 AM Eastern Daylight Saving Time)**
- **Roll Call**
- **Therapeutic Class Reviews**

  Members of the DHA Pharmacy Operations Division (POD) Formulary Management Branch (FMB) will present relative clinical and cost-effective analyses along with the DoD Pharmacy & Therapeutics Committee (P&T) recommendations for the Uniform Formulary (UF) and any recommended Tier 4/Not Covered candidates.

  The P&T Committee made recommendations for the following drugs/drug classes during the August 2022 meeting:

  - **Drug Class Reviews**
    - *Antidepressant and Non-Opioid Pain Agents*
      - *Selective Serotonin Reuptake Inhibitors (SSRIs) subclass*
      - *Selective Serotonin/Norepinephrine Reuptake Inhibitors (SNRIs) subclass*
      - *Norepinephrine/Dopamine Reuptake Inhibitors (NDRIs) subclass*
      - *Gamma-Aminobutyric Acid Analogs (GABAs) subclass*
    - *Overactive Bladder Agents (OAB)*
      - *Beta3 (β-3) Adrenergic Agonists subclass*

  - **Newly Approved Drugs per 32 CFR 199.21(g)(5)**
    - *alpelisib (Vijoice) – Oncological agent for PIK3CA-related overgrowth spectrum (PROS)*
    - *amlodipine oral solution (Norliqva) – Dihydropyridine Calcium Channel Blocker (CCB) alternate dosage form for hypertension*
    - *baclofen oral granules (Lyvispah) – Skeletal Muscle Relaxant; alternative formulation of baclofen for multiple sclerosis spasticity*
    - *benzoyl peroxide 5% cream (Epsolay) – keratolytic for rosacea*
    - *cyclosporine 0.1% ophthalmic emulsion (Verkazia) – Ophthalmic agent for vernal keratoconjunctivitis*

- *daridorexant (Quviviq) – Sleep Disorders: dual orexin receptor antagonist (DORA) for treating insomnia*
- *donepezil patch (Adlarity) – Alzheimer's agent for mild, moderate, to severe dementia and a patch version of an available oral agent*
- *edaravone oral suspension (Radicava ORS) – Miscellaneous Neurological Agent for amyotrophic lateral sclerosis (ALS) and a new oral version of an IV medication*
- *ganaxolone oral suspension (Ztalmy) – Anticonvulsant for treating seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency*
- *insulin glargine solostar unbranded authorized biologic (from Winthrop labs) – Basal insulin*
- *leuprolide SC injection (Camcevi Kit) – Leuprolide-hormone-release hormone (LHRH) agent for treatment of advanced prostate cancer*
- *mavacamten (Camzyos) – Miscellaneous Cardiovascular Agent for symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy*
- *tapinarof 1% cream (Vtama) – Psoriasis Agent*
- *testosterone undecanoate 112.5 mg capsule (Tlando) – Oral Testosterone Replacement Therapy*
- *tirzepatide SC injection (Mounjaro) – Glucagon-like peptide-1 (GLP-1) receptor agonist for type 2 diabetes*
- *vonoprazan/amoxicillin (Voquezna Dual Pak) – Miscellaneous Anti-infective for Helicobacter pylori (H. pylori) infection*
- *vonoprazan/amoxicillin/clarithromycin; (Voquezna Triple Pak) – Miscellaneous Anti-infective for Helicobacter pylori (H. pylori) infection*

- **Utilization Management Issues**

  - **Prior Authorization Criteria—New Manual PA Criteria**

    - *Pulmonary II Agents: Long-Acting Muscarinic Antagonists (LAMAs)—tiotropium dry powder inhaler (Spiriva HandiHaler)*

  - **New Manual PA Criteria for Newly Approved Drugs Not Subject to 32 CFR 199.21(g)(5)**

    - *Non-Insulin Diabetes Drugs: Biguanides subclass—metformin immediate release (IR) 625 mg tablets*
    - *Renin-Angiotensin Anti-hypertensives (RAAs)—valsartan 20 mg/5 mL oral solution*

  - **Prior Authorization Criteria—Updated PA Criteria for New FDA-Approved Indications**

    - *Atopy Agents (Formulary Respiratory Interleukins)—dupilumab injection (Dupixent)*
    - *Targeted Immunomodulatory Biologics (TIBs)—upadacitinib (Rinvoq)*
    - *TIBs—apremilast (Otezla)*
    - *Attention Deficit Hyperactivity Disorder (ADHD): Non-Stimulants—viloxazine extended release (Qelbree)*
    - *Miscellaneous Metabolic Agents—setmelanotide injection (Imcivree)*

  - **Prior Authorization Criteria—Removal of Prior Authorization**

    - *Topical Acne and Rosacea Agents—azelaic acid 15% (Finacea, generics)*
    - *Respiratory Agents Miscellaneous—epinephrine Auto-Injector (Auvi-Q)*

  - **Prior Authorization Criteria—Removal of Indication**

    - *Oncologic Agents – Poly Adenosine Diphosphate Ribose Polymerase-(PARP) Inhibitor: rucaparib (Rubraca)*
    - *Oncologic Agents – Non-Bruton Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (non-BTKIs for CLL/SLL): duvelisib (Copiktra)*

- **Removal of Brand Over Generic Authorization**

  - *Inhaled Corticosteroids: fluticasone propionate hydrofluoroalkane (Flovent HFA)*

- *G1·1 Agents: Aminosalicylates Subclass: mesalamine 1.2 gm (Lialda)*

- **National Defense Authorization Act (NDAA) 2017 Pilot Program: Incorporation of Value-Based Health Care in Purchased Care Component of TRICARE and Medication**
    - *Basal Insulins: insulin glargine (Lantus) Tier 1 copay*

- **Panel Discussions**

  The Beneficiary Advisory Panel members will have the opportunity to ask questions to each of the presenters. Upon completion of the presentation and any questions, the Panel will concur or non-concur on the recommendations of the P&T Committee concerning the establishment of the UF and subsequent recommended changes. The Panel will provide comments on their vote as directed by the Panel Chairman. Comments to the Director, DHA, or their designee will be considered before making a final UF decision.